


# New Blockbuster Alzheimer's Drug Threatens to Break the Bank!

The FDA recently approved a new Alzheimer's medication, Aduhelm (aducanumab). While the scientific community has doubts regarding its safety and effectiveness, manufacturer Biogen initially set the price at **\$56,000 annually**.\*



**Sources:** Juliette Cubanski, Kaiser Family Foundation, "FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries," June 10, 2021, [available here](#)\*

Grace A. Lin, MD, et. al, Institute for Clinical and Economic Review, "Aducanumab for Alzheimer's Disease: Effectiveness and Value," May 5, 2021, [available here](#)

Joseph Antos, American Enterprise Institute, "The Alzheimer's drug is half price. What should Medicare do now?," Dec. 27, 2021, [available here](#)